Bayer (BAYRY), 'Nubeqa' shows 71% risk reduction…Secures successive FDA priority reviews
Bayer is strengthening its presence in the global pharmaceutical market by announcing positive clinical results for its prostate cancer drug 'Nubeqa' and securing multiple FDA priority reviews.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 8+/10 (~1-3 per day, no spam). Verified 30d hit rate 50.1%.